Literature DB >> 12498768

Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder.

Thipparat Suwanmanee1, Halina Sierakowska, Suthat Fucharoen, Ryszard Kole.   

Abstract

A HeLa cell line stably expressing the human beta-globin gene carrying thalassemic mutations beta(E)/IVS1-6 served as a thalassemia model for repair of aberrant splicing of beta(E)-globin pre-mRNA with antisense oligonucleotides. Treatment of beta(E)/IVS1-6 HeLa cells with a morpholino oligonucleotide targeted immediately upstream of the aberrant 5' splice site activated by the mutations resulted in an increase in the amount of correctly spliced beta(E)-globin mRNA in a dose-dependent and sequence-specific fashion. The repaired beta(E)-globin mRNA was stable and could be translated into full-length beta(E)-globin polypeptide. Application of the same oligonucleotide to erythroid progenitor cells from two beta-thalassemia/HbE patients resulted in an approximately 70% increase in correct beta(E)-globin mRNA and 36% increase in hemoglobin E. The erythroid progenitor cells represent the actual targets for the clinical application of antisense repair of defective pre-mRNAs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498768     DOI: 10.1006/mthe.2002.0805

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  25 in total

Review 1.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 2.  Targeted genetic repair: an emerging approach to genetic therapy.

Authors:  Bruce A Sullenger
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

3.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 5.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

6.  A gain of function mutation causing skeletal overgrowth in the rapunzel mutant.

Authors:  Julie Green; Jennifer J Taylor; Anna Hindes; Stephen L Johnson; Matthew I Goldsmith
Journal:  Dev Biol       Date:  2009-07-24       Impact factor: 3.582

Review 7.  Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells.

Authors:  Jessica L Childs-Disney; Matthew D Disney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-22       Impact factor: 13.820

Review 8.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

9.  Genomic features defining exonic variants that modulate splicing.

Authors:  Adam Woolfe; James C Mullikin; Laura Elnitski
Journal:  Genome Biol       Date:  2010-02-16       Impact factor: 13.583

10.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates.

Authors:  Martin M Fabani; Michael J Gait
Journal:  RNA       Date:  2007-12-11       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.